Folotyn for Non-Hodgkin's Lymphoma Auburn NY

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Local Companies

Peter Sadowitz
315-488-9162
Camillus, NY
MARGARET BOUFAL, DO
(315) 255-3331
17 E Genesee Street
Auburn, NY
NORMAN KRAUSE, MD
(607) 257-0157
77 Nelson Street
Auburn, NY
Peter David Sadowitz, MD
315-488-9162
2731 W Foxhill Ln
Camillus, NY
Health Services
(585) 275-5830

Rochester, NY
Roger Tinsley
315-255-3331
82 Copeland Ave
Auburn, NY
Michael W Graber
(315) 492-5096
4900 Broad Rd
Syracuse, NY
ROGER TINSLEY, MD
(315) 255-3331
17 E Genesee Street
Auburn, NY
Roger Wendell Tinsley, MD
315-255-3331
17 E Genesee St Ste 101
Auburn, NY
Gerard M Mc Phee, MD
315-492-6284
4910 Broad Rd
Syracuse, NY
Data Provided by:
    

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Green Tea and Hematologic Malignancies Auburn NY
Read more about Green Tea May Lower the Risk of Hematologic Malignancies.
- Donor Stem-Cell Transplant for Acute Myeloid Leukemia Auburn NY